We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





First-Ever Clinical T-Cell Based Test for Patients Confirms Recent or Prior COVID-19 Infection

By LabMedica International staff writers
Posted on 01 Mar 2021
Adaptive Biotechnologies Corporation (Seattle, WA, USA) has launched T-Detect COVID, the first clinical T-cell based test to confirm recent or prior COVID-19 infection.

Knowledge of prior COVID-19 infection is critically important for those who believe they may have been infected with the virus but have not been able to confirm a diagnosis. More...
Until now, antibody tests have been the primary way to determine recent or prior COVID-19 infection. T-cell tests take an entirely new approach to determine prior infection by looking at a different but equally important part of our immune system, the T cell. In the setting of COVID-19, T-cell responses arise earlier than antibodies and persist in the blood for longer.

In real-world studies, the first-in-class T-Detect COVID test outperformed leading antibody tests. Patients can order T-Detect COVID online at www.t-detect.com by answering a few eligibility questions through a secure portal. A virtual provider will authorize a prescription and patients can have their blood drawn by a mobile phlebotomist at their home or they can visit one of nearly 2,000 Labcorp patient service centers. Patients will receive an email notification when their results are available, and they can view them via a secure portal. Patients ordering T-Detect COVID have the opportunity to contribute to ongoing research to further the understanding of T cell-based immunity to COVID-19. This is particularly important as scientists work to define immunity and establish correlates of protection to SARS-CoV-2, the virus that causes COVID-19, resulting from natural infection or vaccination. T-Detect is currently under review by the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).

“T-Detect COVID is the first T-cell test for patients and the first product resulting from Adaptive’s TCR-Antigen Map collaboration with Microsoft,” said Adaptive Biotechnologies Chief Executive Officer, Chad Robins. “By mapping the human immune response to COVID-19, we have developed a simple blood-based clinical test to help detect recent or prior infections from our T cells. This approach will be scaled for more accurate and early diagnosis of many infectious diseases, autoimmune disorders and cancer.”

Related Links:
Adaptive Biotechnologies Corporation


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The method combines ultrasonic and fluorescence techniques to track amyloid aggregation in real time (Image Credit: Shutterstock)

Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease

Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more

Pathology

view channel
Image: TRUECAM automatically eliminates ambiguous or uninformative regions in whole-slide pathology images, enhancing the reliability of diagnostic analysis. (Photo courtesy of PolyU)

AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis

Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more

Industry

view channel
Image: HealthTab will distribute the Abbott Afinion 2 Analyzer to NHS-linked pharmacies for hemoglobin A1c (HbA1c) and lipid profile testing. (Photo courtesy of Abbott)

New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies

HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.